Does Extraesophageal Reflux Support the Development of Lung Adenocarcinoma? Analysis of Pepsin in Bronchoalveolar Lavage in Non-Smoker Patients.

extraesophageal reflux lung adenocarcinoma lung sarcoidosis pepsin

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
28 Jul 2024
Historique:
received: 17 06 2024
revised: 20 07 2024
accepted: 25 07 2024
medline: 10 8 2024
pubmed: 10 8 2024
entrez: 10 8 2024
Statut: epublish

Résumé

The significance of extraesophageal reflux as a risk factor in lung adenocarcinoma has been understudied. In this study, we investigated whether extraesophageal reflux leads to higher pepsin concentrations in bronchoalveolar lavage (BAL) in patients with lung adenocarcinoma compared to controls. Subjects were recruited from non-smoker patients (lifelong non-smokers and ex-smokers with more than 5 years of non-smoking history) who had undergone bronchoscopy due to pulmonary abnormalities on a CT scan and met the inclusion criteria. Based on histological verification of the lung process, the patients were divided into three groups: (1) lung adenocarcinoma, (2) pulmonary metastases, and (3) lung sarcoidosis. Lung adenocarcinoma cases were further categorized as central or peripheral. BAL samples collected during bronchoscopy were quantitatively analyzed by enzyme-linked immunosorbent assay (ELISA) to measure pepsin levels. No statistically significant difference in pepsin concentration was observed between the lung adenocarcinoma group and control groups (

Identifiants

pubmed: 39123415
pii: cancers16152687
doi: 10.3390/cancers16152687
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministry of Health of the Czech Republic
ID : RVO
Organisme : Charles University
ID : COOPERATIO, Oncology and Haematology
Organisme : European Regional Development Fund
ID : BBMRI_CZ LM2023033
Organisme : European Regional Development Fund
ID : EF16_013/0001674
Organisme : National Institute for Research of Metabolic and Cardiovascular Diseases - EXCELES
ID : LX22NPO5104

Auteurs

Petra Zemanova (P)

First Clinic of Tuberculosis and Respiratory Diseases, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, 12808 Prague, Czech Republic.
Department of Oncology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, Prague 2, 12808 Prague, Czech Republic.

Michal Vocka (M)

Department of Oncology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, Prague 2, 12808 Prague, Czech Republic.

Zdislava Vanickova (Z)

Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, 12808 Prague, Czech Republic.

Frantisek Liska (F)

Institute of Biology and Medical Genetics, Purkyne Institute, First Faculty of Medicine, Charles University in Prague, Albertov 4, 12800 Prague, Czech Republic.

Ludmila Krizova (L)

Department of Oncology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, Prague 2, 12808 Prague, Czech Republic.

Josef Kalab (J)

First Clinic of Tuberculosis and Respiratory Diseases, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, 12808 Prague, Czech Republic.

Jiri Votruba (J)

First Clinic of Tuberculosis and Respiratory Diseases, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, 12808 Prague, Czech Republic.

Classifications MeSH